Search

Manuka G Ghosh

age ~63

from Granger, IN

Also known as:
  • Mamuka Ghosh

Manuka Ghosh Phones & Addresses

  • Granger, IN
  • South Bend, IN
  • Mishawaka, IN
  • Madison, CT
  • Trenton, NJ
  • Branford, CT
  • Plainsboro, NJ
  • Clifton Heights, PA

Work

  • Company:
    Hsiri therapeutics
    2011
  • Address:
    IN
  • Position:
    Research scientist

Education

  • School / High School:
    University of Notre Dame
    1991 to 1995

Skills

Drug Discovery • Drug Design • Drug Development • Chemistry • Medicinal Chemistry • Organic Chemistry • Organic Synthesis • Carbohydrate Chemistry • Amino Acids/Peptides • Gpcrs • Neuroscience • Pharmacology • Pharmacokinetics • Oncology • Infection • Analytical Chemistry • Nmr • Chromatography • Molecular Modeling • Data Analysis • Dmpk • Adme • Biotechnology • Lead Change • Formulation • Drug Delivery • Cro • Cro Management • Nuclear Magnetic Resonance • Pharmaceutical Industry • Life Sciences • High Performance Liquid Chromatography • Drug Metabolism • Parallel Synthesis • Science

Languages

English • Bengali • Hindi

Industries

Pharmaceuticals

Resumes

Manuka Ghosh Photo 1

Manuka Ghosh

view source
Location:
103 Nursery Ln, Madison, CT 06443
Industry:
Pharmaceuticals
Work:
Hsiri Therapeutics - IN since 2011
Research Scientist

Neurogen Corporation Dec 1999 - 2008
Research Fellow II

Intercardia, Inc. 1996 - 1999
Research Scientist
Education:
University of Notre Dame 1991 - 1995
Calcutta University, Kolkata
Master of Science, Masters
Rajabazar Science College
Master of Science, Masters
Jadavpur University
Doctorates, Doctor of Philosophy
Scottish Church College
Bachelors, Bachelor of Science
Skills:
Drug Discovery
Drug Design
Drug Development
Chemistry
Medicinal Chemistry
Organic Chemistry
Organic Synthesis
Carbohydrate Chemistry
Amino Acids/Peptides
Gpcrs
Neuroscience
Pharmacology
Pharmacokinetics
Oncology
Infection
Analytical Chemistry
Nmr
Chromatography
Molecular Modeling
Data Analysis
Dmpk
Adme
Biotechnology
Lead Change
Formulation
Drug Delivery
Cro
Cro Management
Nuclear Magnetic Resonance
Pharmaceutical Industry
Life Sciences
High Performance Liquid Chromatography
Drug Metabolism
Parallel Synthesis
Science
Languages:
English
Bengali
Hindi

Us Patents

  • 1H-Pyrrolo [3,2-B] Pyridine-3-Carboxylic Acid Amines As Gabaa Receptor Ligands

    view source
  • US Patent:
    6673811, Jan 6, 2004
  • Filed:
    Nov 19, 2002
  • Appl. No.:
    10/299199
  • Inventors:
    George D. Maynard - Clinton CT
    Manuka Ghosh - Branford CT
    Christopher J. ODonnell - Mystic CT
  • Assignee:
    Neurogen Corporation - Branford CT
    Pfizer, Inc. - New York NY
  • International Classification:
    A61K 314965
  • US Classification:
    514300, 51425502, 544405, 546113
  • Abstract:
    Disclosed are 1H-Pyrrolo[3,2-b]pyridine-3-carboxylic acid amides that bind to the benzodiazepine site of GABA receptors. Such compounds can be used to modulate ligand binding to GABA receptors in vivo and in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals, and livestock animals.
  • Benzimidazole And Pyridylimidazole Derivatives

    view source
  • US Patent:
    6916819, Jul 12, 2005
  • Filed:
    Dec 21, 2001
  • Appl. No.:
    10/038069
  • Inventors:
    Guiying Li - Branford CT, US
    John M. Peterson - Madison CT, US
    Pamela Albaugh - Carmel IN, US
    Kevin S. Currie - North Branford CT, US
    Guolin Cai - Thousand Oaks CA, US
    Linda M. Gustavson - Guilford CT, US
    Kyungae Lee - Guilford CT, US
    Alan Hutchison - Madison CT, US
    Vinod Singh - Kanpur, IN
    George D. Maynard - Clinton CT, US
    Jun Yuan - Guilford CT, US
    Ling Hong Xie - Guilford CT, US
    Manuka Ghosh - Branford CT, US
    Nian Liu - North Branford CT, US
  • Assignee:
    Neurogen Corporation - Branford CT
  • International Classification:
    C07D403/12
    C07D403/14
    C07D401/14
    A61K031/4184
    A61P025/24
  • US Classification:
    514256, 514372, 514374, 514378, 514394, 514395, 514339, 514307, 544333, 206570, 546144, 546167, 5462697, 5462714, 5462724, 5462734, 5462737, 548181, 548206, 548235, 548247, 548254, 548255, 5483047, 5483061
  • Abstract:
    This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAreceptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAreceptors in tissue sections.
  • Heteroaryl Substituted Fused Bicyclic Heteroaryl Compound As Gabaa Receptor Ligands

    view source
  • US Patent:
    6936617, Aug 30, 2005
  • Filed:
    Jul 12, 2002
  • Appl. No.:
    10/194852
  • Inventors:
    Alan Hutchison - Madison CT, US
    George Maynard - Clinton CT, US
    Pamela Albaugh - Carmel IN, US
    Linghong Xie - Guilford CT, US
    Jun Yuan - Guilford CT, US
    Scott Mitchell - East Haven CT, US
    Vinod Singh - Kanpur, IN
    Manuka Ghosh - Madison CT, US
    Guiying Li - Branford CT, US
    Nian Liu - North Branford CT, US
  • Assignee:
    Neurogen Corporation - Branford CT
  • International Classification:
    C07D471/04
    C07D487/04
    C07D513/04
    A61K031/437
  • US Classification:
    514256, 514300, 544333, 546121
  • Abstract:
    This invention relates to heteroaryl substituted fused bicyclic heteroaryl compounds, such as heteroaryl substituted imidazopyridines, imidazopyrazines, imidazopyridizines, imidazopyrimidines, and imidazothiazoles, which may be described by Formula I or Formula II: The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAreceptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Processes for preparing compounds of Formula I and Formula II are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I or Formula II in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAreceptors in tissue sections.
  • Substituted 1-Benzyl-4-Substituted Piperazine Analogues

    view source
  • US Patent:
    7253168, Aug 7, 2007
  • Filed:
    Apr 6, 2005
  • Appl. No.:
    11/100355
  • Inventors:
    Alan J. Hutchison - Madison CT, US
    Bertrand L. Chenard - Waterford CT, US
    James G. Tarrant - Hamden CT, US
    Guiying Li - Branford CT, US
    Manuka Ghosh - Madison CT, US
    George P. Luke - Clinton CT, US
    John M. Peterson - Durham CT, US
    Wallace C. Pringle - Guilford CT, US
    Mary-Margaret E. O'Donnell - Shelton CT, US
    Kyungae Lee - Newton MA, US
    Linda M. Gustavson - Ringoes NJ, US
    Dario Doller - Wallingford CT, US
  • Assignee:
    Neurogen Corporation - Branford CT
  • International Classification:
    A07D 241/36
    A61K 31/498
    A61P 3/04
    A61P 3/10
    C07D 239/70
    C07D 487/08
    C07D 471/14
    A61K 31/517
    A61K 31/407
  • US Classification:
    514249, 544349, 544253, 544355, 544238, 544295, 544357, 548453, 514256, 514414, 514314, 514338, 51425211, 514307, 51425202, 546168, 5462767, 546146
  • Abstract:
    Compounds of Formula I are provided, in which variables are as described herein:Such compounds may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e. g. , receptor localization studies).
  • Benzimidazole And Pyridylimidazole Derivatives

    view source
  • US Patent:
    7300945, Nov 27, 2007
  • Filed:
    Jul 12, 2005
  • Appl. No.:
    11/179458
  • Inventors:
    Guiying Li - Branford CT, US
    Pamela Albaugh - Carlsbad CA, US
    Kevin S. Currie - North Branford CT, US
    Guolin Cai - Thousand Oaks CA, US
    Linda M. Gustavson - Ringoes NJ, US
    Kyungae Lee - Newton MA, US
    Alan Hutchison - Madison CT, US
    George D. Maynard - Clinton CT, US
    Jun Yuan - Guilford CT, US
    Ling Hong Xie - Guilford CT, US
    Manuka Ghosh - Madison CT, US
    Nian Liu - Edison NJ, US
    George P. Luke - Clinton CT, US
    Scott Mitchell - East Haven CT, US
    Martin Patrick Allen - North Stonington CT, US
    Spiros Liras - Stonington CT, US
  • Assignee:
    Neurogen Corporation - Branford CT
  • International Classification:
    C07D 471/04
    A61K 31/437
  • US Classification:
    514303, 546118, 206570
  • Abstract:
    This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula IThe invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAreceptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAreceptors in tissue sections.
  • 4,5-Disubstituted-2-Aryl Pyrimidines

    view source
  • US Patent:
    7482350, Jan 27, 2009
  • Filed:
    May 6, 2005
  • Appl. No.:
    11/123755
  • Inventors:
    George D. Maynard - Clinton CT, US
    Manuka Ghosh - Madison CT, US
    Jun Yuan - Guilford CT, US
    Kevin S. Currie - North Branford CT, US
    Scott Mitchell - East Haven CT, US
    Qin Guo - Branford CT, US
    He Zhao - Branford CT, US
  • Assignee:
    Neurogen Corporation - Brandford CT
  • International Classification:
    A01N 43/54
    C07D 239/42
    C07D 401/04
    C07D 403/00
  • US Classification:
    514256, 544295
  • Abstract:
    4,5-disubstituted-2-arylpyrimidines of Formula I and Formula II are provided:.
  • Benzimidazole And Pyridylimidazole Derivatives

    view source
  • US Patent:
    7642267, Jan 5, 2010
  • Filed:
    Nov 19, 2007
  • Appl. No.:
    11/942480
  • Inventors:
    Guiying Li - Branford CT, US
    Pamela Albaugh - Carmel IN, US
    Kevin S. Currie - North Branford CT, US
    Guolin Cai - Thousand Oaks CA, US
    Linda M. Gustavson - Guilford CT, US
    Kyungae Lee - Guilford CT, US
    Alan Hutchison - Madison CT, US
    George D. Maynard - Clinton CT, US
    Jun Yuan - Guilford CT, US
    Ling Hong Xie - Guilford CT, US
    Manuka Ghosh - Branford CT, US
    Nian Liu - North Branford CT, US
    George P. Luke - Clinton CT, US
    Scott Mitchell - East Haven CT, US
    Martin Patrick Allen - North Stonington CT, US
    Spiros Liras - Stonington CT, US
  • Assignee:
    Neurogen Corporation - Branford CT
  • International Classification:
    C07D 471/04
    A61K 31/437
  • US Classification:
    5142621, 544262, 544264, 544265, 544277, 5142632
  • Abstract:
    This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I. The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAreceptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate.
  • 2-Phenoxy Pyrimidinone Analogues

    view source
  • US Patent:
    8003656, Aug 23, 2011
  • Filed:
    Aug 22, 2007
  • Appl. No.:
    11/895286
  • Inventors:
    Rajagopal Bakthavatchalam - Madison CT, US
    Scott M. Capitosti - Middletown CT, US
    Jianjun Xu - Branford CT, US
    Bertrand L. Chenard - Waterford CT, US
    Manuka Ghosh - Madison CT, US
    Charles A. Blum - Westbrook CT, US
  • Assignee:
    Neurogen Corporation - Branford CT
  • International Classification:
    C07D 473/04
    A61K 31/522
    C07D 495/04
    C07D 487/04
    A61K 31/519
    A61P 25/04
  • US Classification:
    5142633, 51426322, 51426334, 5142601, 5142641, 544269, 544267, 544278, 544262, 544279
  • Abstract:
    2-Phenoxy pyrimidinone analogues are provided, of the Formula:.

Get Report for Manuka G Ghosh from Granger, IN, age ~63
Control profile